Please login to the form below

Not currently logged in
Email:
Password:

Celgene and GlobeImmune to collaborate

GlobeImmune has granted exclusive rights to Celgene to develop drugs intended to stimulate the immune system against cancer in a $500m deal

Research biotech GlobeImmune has granted exclusive rights to Celgene Corp to develop drugs intended to stimulate the immune system against cancer in a deal that could be worth more than $500m.

New Jersey-based Celgene will pay GlobeImmune $40m upfront, which includes an equity stake in the privately held company.

GlobeImmune, based in Louisville, will handle early-stage development of the drug candidates, called Tarmogens, and Celgene will have the option to obtain an exclusive global licence to develop and sell the drugs under the partnership.

GlobeImmune's drugs will have to meet various research milestones to trigger further payments from Celgene. The $500m potential total includes royalties Celgene would pay to GlobeImmune on future sales of drugs if they are approved.

The Tarmogen drugs contain a genetically engineered yeast that also contains antibodies designed to fight disease. The drugs are intended to boost the body's immune system. GlobeImmune has one drug, GI-4000, in mid-stage testing against pancreatic and non-small cell lung cancer. 

"The partnership with GlobeImmune supports our goal to identify and develop high-potential oncology therapies based on significant, innovative science," said Thomas Daniel, president of research for Celgene. "The Tarmogen technology has the potential to address a number of highly defined unmet medical needs."

18th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics